
Feature|Articles|July 14, 2026
Medicaid Fraud Crackdown Intensifies, But Is It Solving the Right Problem?
Author(s)Pearl Steinzor
Fact checked by: Maggie L. Shaw
CMS's enforcement surge has put every Medicaid Fraud Control Unit under review, but experts say the bigger driver of coverage loss may be red tape.
Advertisement
Advertisement
In January 2026, Minnesota received a letter from CMS announcing it would begin withholding $515 million in quarterly federal Medicaid payments, citing unresolved program integrity concerns.1 The state sued. A federal court dismissed the case on procedural grounds in April, and even after CMS accepted Minnesota's corrective action plan the following month, the withheld funds were not released.2 By May, CMS had gone further still, deferring $1.3 billion in federal Medicaid funding to the state—the largest deferral action in the agency's history.3
Related to this article

Employer diabetes guide; Camden psychedelic therapy input; CRC after EMR; rural HFrEF care; JAMA obesity report.

An employer coalition's new guide outlines how workplaces can prevent and manage diabetes, from benefit design to accommodations.

Panelists concurred that precision medicine can serve to exacerbate care inequality if not everyone can access these therapeutics.

Pooled real-world data show an 88% response rate with brexu-cel in relapsed mantle cell lymphoma (MCL), but cost and QOL data are scarce.

CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.

New York hepatitis B experts say screening gaps and weekly monitoring demands could limit who benefits from the first functional cure therapy.

Real-world acne treatment adherence spans 6% to 84%, with cost, adverse effects, and slow results driving nonadherence.
Advertisement
Advertisement

